杭州帕琦斯医药科技

Pagos Pharmaceutical is a biotechnology company headquartered in Hangzhou, China, dedicated to the discovery of innovative small molecule drugs targeting protein-protein interactions (PPI). The company utilizes its proprietary Pagos-PPI platform, which combines structural biology, AI-driven design, and high-throughput screening to tackle challenging targets in oncology and immunology. Founded in 2021 by experienced drug hunters from global pharmaceutical firms, Pagos aims to develop next-generation therapies for patients with high unmet medical needs. Its lead program, PGS-001, is a potent SOS1 inhibitor designed to treat KRAS-mutant solid tumors. The company is backed by prominent investors including Lilly Asia Ventures and Qiming Venture Partners.